| 09/14/2026 3:01 PM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/11/2026 3:44 PM | Yarrow Bioscience (1566044) Filer | Form 424B5 | |
| 09/11/2026 3:52 PM | Yarrow Bioscience (1566044) Filer | Form 424B5 | |
| 09/10/2026 3:01 PM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/19/2026 11:15 PM | Yarrow Bioscience (1566044) Filer | Form EFFECT | |
| 08/14/2026 8:32 PM | ADAR1 Capital Management, LLC (1940272) Filed by Yarrow Bioscience (1566044) Subject | Form SCHEDULE 13G | |
| 08/13/2026 3:03 PM | Yarrow Bioscience (1566044) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/13/2026 9:00 AM | Yarrow Bioscience (1566044) Subject Zhang Xiaofan (2140685) Filed by | Form SCHEDULE 13G/A | |
| 08/07/2026 6:51 PM | Logos Global Management LP (1792126) Filed by Yarrow Bioscience (1566044) Subject | Form SCHEDULE 13G/A | |
| 08/07/2026 11:51 AM | Janus Henderson Group Ltd. (1274173) Filed by Yarrow Bioscience (1566044) Subject | Form SCHEDULE 13G | |
| 08/05/2026 8:08 PM | ORBIMED ADVISORS LLC (1055951) Filed by Yarrow Bioscience (1566044) Subject | Form SCHEDULE 13D | |
Get the Latest News and Ratings for YARW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Yarrow Bioscience and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/04/2026 1:12 PM | Logos Global Management LP (1792126) Filed by Yarrow Bioscience (1566044) Subject | Form SCHEDULE 13G | |
| 07/30/2026 3:01 PM | RTW Fund Group GP, LLC (2147397) Reporting WONG RODERICK (1493280) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/30/2026 3:03 PM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/30/2026 3:05 PM | RTW Fund Group GP, LLC (2147397) Reporting WONG RODERICK (1493280) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/30/2026 3:06 PM | RTW Fund Group GP, LLC (2147397) Filed by Yarrow Bioscience (1566044) Subject | Form SCHEDULE 13G | |
| 07/29/2026 8:00 PM | Frey Rebecca (2145132) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:03 PM | Ryder Steven (1872868) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:05 PM | Payton Lori (2144768) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:08 PM | Alford Rachael (2143892) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:11 PM | Hoerter Steven L. (1533451) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:15 PM | Lundberg Sven Ante (1682126) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:17 PM | Silverman Peter B. (1790314) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:20 PM | White William Richard (1778739) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:21 PM | Ashiya Mona (1794070) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:26 PM | ORBIMED ADVISORS LLC (1055951) Reporting OrbiMed Capital GP X LLC (2140741) Reporting OrbiMed Genesis GP LLC (1808744) Reporting Yarrow Bioscience (1566044) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/29/2026 8:33 PM | Yarrow Bioscience (1566044) Issuer Zeronda Tyler (1867033) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/29/2026 8:36 PM | Ashiya Mona (1794070) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/21/2026 7:14 AM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/17/2026 7:41 PM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/17/2026 8:54 AM | Yarrow Bioscience (1566044) Subject Zhang Xiaofan (2140685) Filed by | Form SCHEDULE 13G/A | |
| 07/14/2026 9:06 AM | Yarrow Bioscience (1566044) Subject Zhang Xiaofan (2140685) Filed by | Form SCHEDULE 13G/A | |
| 07/14/2026 7:12 AM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/14/2026 7:14 AM | Yarrow Bioscience (1566044) Subject | Form 425 | |
| 07/10/2026 7:06 AM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/10/2026 7:07 AM | Yarrow Bioscience (1566044) Subject | Form 425 | |
| 07/02/2026 7:05 PM | Domzalski David (1727794) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/02/2026 7:05 PM | Harsch Mutya (1727809) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/02/2026 7:05 PM | Stuart Iain (1727756) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/02/2026 7:05 PM | Yarrow Bioscience (1566044) Issuer Zeronda Tyler (1867033) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/16/2026 11:15 PM | Yarrow Bioscience (1566044) Filer | Form EFFECT | |
The trade I’ve been waiting for since 2011 (Ad) Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply.
But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle. Watch the free video briefing and learn the No. 1 trade to leverage rising gold |
| 06/16/2026 8:45 AM | Yarrow Bioscience (1566044) Filer | Form ARS | |
| 06/15/2026 3:46 PM | Yarrow Bioscience (1566044) Filer | Form 424B3 | |
| 06/15/2026 1:24 PM | Yarrow Bioscience (1566044) Subject Zhang Xiaofan (2140685) Filed by | Form SCHEDULE 13G | |
| 06/03/2026 8:29 AM | Yarrow Bioscience (1566044) Filer | Form S-4/A | |
| 05/21/2026 4:00 PM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 3:04 PM | Yarrow Bioscience (1566044) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/28/2026 4:28 PM | Yarrow Bioscience (1566044) Filer | Form S-4/A | |
| 03/31/2026 4:28 PM | Yarrow Bioscience (1566044) Filer | Form S-4 Registration statement under Securities Act of 1933 | |
| 03/11/2026 3:57 PM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/27/2026 7:01 AM | Yarrow Bioscience (1566044) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 01/30/2026 3:10 PM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/30/2026 3:11 PM | Yarrow Bioscience (1566044) Subject | Form 425 | |
| 01/05/2026 7:30 AM | Harsch Mutya (1727809) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 7:30 AM | Stuart Iain (1727756) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 7:30 AM | Yarrow Bioscience (1566044) Issuer Zeronda Tyler (1867033) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 7:30 AM | Domzalski David (1727794) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/17/2025 7:15 AM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/17/2025 7:16 AM | Yarrow Bioscience (1566044) Subject | Form 425 | |
| 12/15/2025 3:15 PM | Basta Steven L (1417397) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/15/2025 3:15 PM | LEPORE PATRICK G (1055404) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/15/2025 3:15 PM | Little Elisabeth Sandoval (1632295) Reporting Yarrow Bioscience (1566044) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 3:06 PM | CITADEL ADVISORS LLC (1423053) Filed by Yarrow Bioscience (1566044) Subject | Form SCHEDULE 13G/A | |
| 11/14/2025 2:23 PM | EVENTIDE ASSET MANAGEMENT, LLC (1442891) Filed by Yarrow Bioscience (1566044) Subject | Form SCHEDULE 13G/A | |
| 11/14/2025 12:10 PM | Cormorant Asset Management, LP (1583977) Filed by Yarrow Bioscience (1566044) Subject | Form SCHEDULE 13G/A | |
| 11/12/2025 3:07 PM | Yarrow Bioscience (1566044) Filer | Form DEF 14A | |
| 11/06/2025 7:02 AM | Yarrow Bioscience (1566044) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |